Re: Ally Bridge strategy
"Cash, no?"
I've never been part of a privatization transaction, but I can't see a viable option to a cash settlement. I spent many years following and investing in Exelixis, and - for all the talk of buyout - it hasn't happened yet...despite all Cabo's published successes. I mention this because for all we know about BIOC, there are lots of unaddressed matters that are worthy of consideration. For example, it's typical of these smaller LB companies to publish not only on their available commercial targets - but also on their research-use targets. Not so here...
They have also claimed business affiliation with "a large, multi-center, nationwide cancer center", yet have not mentioned a name for this organization. They have issued a ream of press releases, naming collaborators of both academic and clinical venue - but really haven't reported much in the way of results of late. Two new commercially-available targets this year, but how many more are in process? How about some research updates? How about a breakdown on revenue sources? How about an update on Quest Mexico, Shilpa Gupta, and the Rosetta collaboration?
This company owes shareholders a monstrously voluminous update...